Dare Bioscience, Inc.

DARE ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012
Operating Activities
Net Income $-11.5M $-672.7K $-39.6M $-23.3M $-17.1M $-22.1M
Depreciation & Amortization $261.0K $192.0K $126.0K $197.0K $346.0K
Depreciation $0
Amortization
Stock-Based Compensation $15.8K $9.0K $2.4M $885.0K $622.0K $529.0K
Net Cash from Operating Activities $-2.5M $-372.3K $-31.9M $-19.1M $-16.6M $-21.0M
Investing Activities
Capital Expenditures $0 $535.0K $277.0K $225.0K $7.0K $180.0K
Business Acquisitions
Net Cash from Investing Activities $9.9M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $155.0K
Net Change in Cash $7.5M $-174.8K $24.7M $45.7M $-11.2M $1.4M
Free Cash Flow $-2.5M $-907.3K $-32.2M $-19.3M $-16.6M $-21.2M
← Newer Page 2 of 2 Older →